misitatug blivedotin (RC88) / Rongchang Pharma  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
misitatug blivedotin (RC88) / Rongchang Pharma
RC88-C008, CTR20233195: A multicenter, single-arm phase II clinical study to evaluate the efficacy, safety, and pharmacokinetics of RC88 in platinum-resistant recurrent epithelial ovarian, fallopian tube, and primary membrane cancer

Not yet recruiting
2
88
China
RC88 - Rongchang Pharma
Remegen Biopharmaceutical (Yantai) Co., Ltd./ Remegen Biopharmaceutical (Yantai) Co., Ltd
Platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer
 
 
NCT06173037: RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Not yet recruiting
2
88
RoW
RC88, RC88 for Injection
RemeGen Co., Ltd.
Primary Peritoneal Cancer, Fallopian Tube, Epithelial Ovarian
06/26
12/26
NCT04175847: A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors

Recruiting
1/2
200
RoW
RC88, RC88 for Injection
RemeGen Co., Ltd.
Solid Tumor
09/24
09/25
NCT05804526: A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours

Recruiting
1/2
82
RoW
RC88, Sintilimab Injection, Sintilimab
RemeGen Co., Ltd.
Advanced Solid Tumours
05/25
12/25

Download Options